Client News

Home/Client News
Client News 2018-08-28T11:24:45+00:00
October 14, 2019
PolarityTE Announces Positive Pilot Study Data of SkinTE as a Treatment for Venous Stasis Leg Ulcers
PolarityTE, Inc. (PTE), a biotechnology company developing and commercializing regenerative tissue products and biomaterials, today announced findings from an open-label, single-arm pilot study, which examined ...
October 14, 2019
Bellerophon to Present New Data from Cohort 1 of Ongoing Phase 2/3 Study of INOpulse® for Treatment of Pulmonary Hypertension Associated with Interstitial Lung Disease at CHEST 2019 Annual Meeting
WARREN, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Bellerophon Therapeutics, Inc. (BLPH) (“Bellerophon” or the “Company”), a clinical-stage biotherapeutics company, today announced that it will ...
October 14, 2019
Onxeo Receives EPO Intent-to-Grant Notice for New Patent Strengthening European Protection of Compounds Sourced From its platON™ Platform
Onxeo S.A. (Euronext Paris, NASDAQ Copenhagen: ONXEO), (“Onxeo” or “the Company”), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA ...
October 11, 2019
Kodiak Sciences Treats First Patients in DAZZLE Pivotal Study of KSI-301 in Wet Age-Related Macular Degeneration
PALO ALTO, Calif., Oct. 10, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ...
October 11, 2019
Kodiak Sciences to Host R&D Day on October 14 in San Francisco to Highlight Recent Clinical Progress and Development Planning for KSI-301
PALO ALTO, Calif., Oct. 11, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD) will host an R&D Day in San Francisco to highlight significant progress in ...
October 11, 2019
Emmaus Life Sciences Reports Preliminary Gross Sales for the Three Months Ended September 30, 2019
TORRANCE, Calif., Oct. 11, 2019 (GLOBE NEWSWIRE) -- Emmaus Life Sciences, Inc. (OTCQB: EMMA), a leader in sickle cell disease (SCD) treatment, today reported preliminary ...
October 11, 2019
Phio Pharmaceuticals Announces Adjournment of 2019 Annual Meeting of Stockholders
MARLBOROUGH, Mass., Oct. 11, 2019 /PRNewswire/ -- Phio Pharmaceuticals Corp. (PHIO), a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary ...
October 11, 2019
Pfenex Provides Update for PF708 Outside the United States
SAN DIEGO, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) today announced that its partner Alvogen has entered into exclusive commercialization agreements ...
October 11, 2019
NeuBase Therapeutics Announces Appointment of Cancer Biologist and RNA Therapeutics Specialist Steven Dowdy, Ph.D., to Scientific Advisory Board
PITTSBURGH, Oct. 11, 2019 (GLOBE NEWSWIRE) -- NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase” or the “Company”), a biotechnology company developing next-generation antisense therapies to address ...
October 11, 2019
RedHill Biopharma Announces Full Results from Positive MAP US Phase 3 Study and Supportive Top-Line Results from MAP US2 Open-Label Extension Study with RHB-104 in Crohn’s Disease
TEL-AVIV, Israel and RALEIGH, N.C., Oct. 11, 2019 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (Nasdaq: RDHL) (Tel-Aviv Stock Exchange: RDHL) (“RedHill” or the “Company”), a ...
October 11, 2019
Reata Pharmaceuticals, Inc. Announces Presentations at the American Society for Nephrology Kidney Week 2019
IRVING, Texas, Oct. 11, 2019 (GLOBE NEWSWIRE) -- Reata Pharmaceuticals, Inc. (RETA), a clinical-stage biopharmaceutical company, today announced that three abstracts highlighting clinical and nonclinical ...
October 7, 2019
ASIT biotech Receives GMP Certification for its Manufacturing Site in Liège, Belgium
BRUSSELS, Belgium, Oct. 07, 2019 (GLOBE NEWSWIRE) -- ASIT biotech (ASIT - BE0974289218), a clinical stage biopharmaceutical company focused on the research, development and future ...
October 7, 2019
Quantum Genomics Enters Into Exclusive Negotiations for its First Partnership
PARIS and NEW YORK, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Quantum Genomics (Euronext Growth - FR0011648971 - ALQGC, OTCQX - QNNTF), a biopharmaceutical company specializing in developing ...
October 7, 2019
Pfenex Receives U.S. FDA Approval for PF708 to Treat Osteoporosis
SAN DIEGO, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Pfenex Inc. (NYSE American: PFNX) announced today that the U.S. Food and Drug Administration (FDA) has approved ...
October 7, 2019
Kodiak Sciences Announces Upcoming Presentation of Durability Data from Clinical Development Program of KSI-301 in Wet AMD, DME, and RVO at American Academy of Ophthalmology 2019 Annual Meeting
PALO ALTO, Calif., Oct. 7, 2019 /PRNewswire/ -- Kodiak Sciences Inc. (KOD), a clinical stage biopharmaceutical company specializing in novel therapeutics to treat chronic, high-prevalence ...
October 7, 2019
ProQR to Present Top-Line Results from the Phase 1/2 Study of Sepofarsen in LCA10 Patients ahead of AAO
LEIDEN, the Netherlands & CAMBRIDGE, Mass., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ProQR Therapeutics N.V. (PRQR), a company dedicated to changing lives through the creation of transformative RNA medicines ...
October 7, 2019
ADMA Biologics Announces Data Presented at IDWeek 2019
RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (ADMA) (“ADMA” or the “Company”), a vertically integrated commercial biopharmaceutical ...
October 7, 2019
ProFound AI™ Platform Featured at Journées Francophones de Radiologie Congress in Paris
NASHUA, N.H. and PARIS, Oct. 07, 2019 (GLOBE NEWSWIRE) -- iCAD, Inc. (ICAD), a global medical technology leader providing innovative cancer detection and therapy solutions, ...
October 7, 2019
Zogenix Presents Positive Clinical Study Results for Investigational Treatment for TK2 Deficiency
EMERYVILLE, Calif., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (ZGNX), a global pharmaceutical company developing rare disease therapies, and its wholly-owned subsidiary, Modis Therapeutics, ...
October 7, 2019
DURECT Announces Completion of Enrollment in its Phase 2a Clinical Trial of DUR-928 in Psoriasis and 50% Enrollment in its Phase 1b DUR-928 Clinical Trial in NASH
CUPERTINO, Calif., Oct. 7, 2019 /PRNewswire/ -- DURECT Corporation (DRRX) today announced that it has completed enrollment in its Phase 2a clinical trial of topical DUR-928 in ...
Page 3 of 169